Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity

Among breast cancer patients, those diagnosed with the triple-negative breast cancer (TNBC) subtype have the worst prog-nosis. TNBC does not express estrogen receptor-alpha, progesterone receptor, or the HER2 oncogene; therefore, TNBC lacks targets for molecularly-guided therapies. The concept that...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Bin, Mitrea, Cristina, Wijesinghe, Priyanga, Marchetti, Luca, Girsch, Emily, Farr, Rebecca L., Boerner, Julie L, Mohammad, Ramzi, Dyson, Greg, Terlecky, Stanley R., Bollig-Fischer, Aliccia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345072/
https://www.ncbi.nlm.nih.gov/pubmed/28281569
http://dx.doi.org/10.1038/srep44125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345072/
https://www.ncbi.nlm.nih.gov/pubmed/28281569
http://dx.doi.org/10.1038/srep44125

Ejemplares similares